Cardiac vulnerability.
D000200:Action Potentials; D000368:Aged; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology*; D001919:Bradycardia / Q000503:physiopathology; D003331:Coronary Vessels / Q000503:physiopathology; D004056:Differential Threshold; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D004558:Electric Stimulation; D004562:Electrocardiography; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D006339:Heart Rate; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006947:Hyperkalemia / Q000150:complications / Q000503:physiopathology; D007511:Ischemia / Q000503:physiopathology; D008297:Male; D008564:Membrane Potentials; D009203:Myocardial Infarction / Q000503:physiopathology; D011312:Pressure; D014693:Ventricular Fibrillation / Q000209:etiology / Q000503:physiopathology*; D014927:Wolff-Parkinson-White Syndrome / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents